AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2195937
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (Group B)
Trial: 29118299
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol)
Trial: 24817596
Drug: Glucose solution
RxNorm normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solution (reference food)
Trial: 22569355
Drug: Piperacillin population
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin population pharmacokinetics
Trial: 11952478
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using verteporfin
Trial: 11952478
Drug: Anti-vascular endothelial
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-vascular endothelial growth factor (VEGF) agents
Trial: 7614522
Drug: Loracarbef 200
RxNorm normalized name: loracarbef 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loracarbef 200 mg BID
Trial: 7614522
Drug: Loracarbef 400
RxNorm normalized name: loracarbef 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loracarbef 400 mg BID
Trial: 2645756
Drug: Benazepril 40
RxNorm normalized name: benazepril 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 40 mg once daily
Trial: 2645756
Drug: Benazepril 80
RxNorm normalized name: Bénazépril
DrugBank: Benazepril (DB00542)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benazepril 80 mg once daily
Trial: 495045
Drug: hypertonic glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypertonic glycerol infusion plus dexamethasone
Trial: 26103528
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g intravenous cefazolin
Trial: 26103528
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g intravenous cefazolin
Trial: 26103528
Drug: Both 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 2 g and 3 g intravenous cefazolin
Trial: 21875678
Drug: Sinovial(®) (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinovial(®) (16 mg/2 ml, 0.8% highly purified intra-articular hyaluronic acid)
Trial: 21875678
Drug: Synvisc(®) (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synvisc(®) (16 mg/2 ml, 0.8% hylan G-F20)
Trial: 17388716
Drug: Cyproterone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone (100 mg/day)
Trial: 17388716
Drug: Haloperidol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (2 mg/day)
Trial: 17201083
Drug: Heparin-concentration-based system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-concentration-based system (HMS)
Trial: 10368245
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL of 2% lidocaine gel administered intrarectally 15 min before biopsies (group 1)
Trial: 10368245
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL of trans-sonic hydrophilic gel administered transrectally (placebo, group 2)
Trial: 8683250
Drug: Oral cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cladribine 10 mg/m2/d for 5 consecutive days in monthly courses
Trial: 1913759
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (0.3 mg sublingual)
Trial: 1913759
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg orally)
Trial: 1913759
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 mg orally)
Trial: 6814225
Drug: Verapamil, 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil, 480 mg daily
Trial: 30643924
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg glucagon after 45 min of cycling
Trial: 30643924
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg glucagon before cycling
Trial: 26377322
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (A)
Trial: 26377322
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (B)
Trial: 26377322
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy plus massage therapy (C)
Trial: 15208206
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy based on estrogen receptor content
Trial: 16200721
Drug: Soybean lecithin
RxNorm normalized name: soybean lecithin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean lecithin 10 g tid
Trial: 16200721
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Basic treatment group)
Trial: 9635386
Drug: premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: premixed insulin administered by pen
Trial: 7944878
Drug: m-Chlorophenylpiperazine (MCPP)
RxNorm normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-Chlorophenylpiperazine (MCPP) 0.1 mg/kg
Trial: 7944878
Drug: yohimbine hydrochloride
RxNorm normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: yohimbine hydrochloride 0.4 mg/kg
Trial: 25468636
Drug: Double low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double low protocol (iodixanol at 270 mg iodine/ml, 100 kVp tube voltage, AIDR)
Trial: 25468636
Drug: Conventional protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional protocol (iopamidol at 370 mg iodine/ml, 120 kVp tube voltage, FBP)
Trial: 8751023
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments including grapefruit juice
Trial: 8751023
Drug: Treatments including
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments including grapefruit juice
Trial: 2236369
Drug: Cognitive‐behavioural therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioural therapy (average number of sessions: 7.2)
Trial: 30335626
Drug: Pregabalin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150 mg twice daily, n = 40)
Trial: 25457902
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg macitentan
Trial: 25457902
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg macitentan
Trial: 21854292
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation treatment (group counseling weeks 1-8 + transdermal nicotine patch 21 mg/day weeks 1-6; 14 mg/day weeks 7-8)
Trial: 21854292
Drug: Substance abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance abuse treatment as usual
Trial: 17596218
Drug: ketamine-propofol admixture
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine-propofol admixture (0.5 mg/ml ketamine in 10 mg/ml propofol)
Trial: 17596218
Drug: lidocaine-propofol admixture
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine-propofol admixture (1 mg/ml lidocaine in 10 mg/ml propofol)
Trial: 15294063
Drug: Pulmicort Turbuhaler
RxNorm normalized name: Pulmicort Turbuhaler
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulmicort Turbuhaler (budesonide inhalation powder) two puffs (400 microg) bid
Trial: 15294063
Drug: pressurized metered-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pressurized metered-dose inhalers (pMDIs)
Trial: 9169397
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin treatment (insulin-glucose infusion for at least 24 hours followed by multidose insulin treatment)
Trial: 9169397
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin treatment (in predefined group without previous insulin treatment and low cardiovascular risk)
Trial: 9169397
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (control group in predefined group without previous insulin treatment and low cardiovascular risk)
Trial: 28361971
Drug: PG2 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG2 (500 mg, IV) administered 3 doses per week for 2 weeks
Trial: 23433461
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy for 48 months (clopidogrel plus aspirin)
Trial: 23433461
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy for 12 months (clopidogrel plus aspirin)
Trial: 12577352
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with Guben Yiliu III (GBYL)
Trial: 12577352
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with moxibustion and Guben Yiliu III (GBYL)
Trial: 2427836
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg (pretreatment)
Trial: 25187399
Drug: Bapineuzumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab (6 doses intravenously once every 13 weeks)
Trial: 18353720
Drug: Carperitide infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carperitide infusion (group II)
Trial: 10869261
Drug: Cariporide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariporide (40 mg intravenous bolus)
Trial: 9374084
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles over 24 weeks
Trial: 9374084
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with oral cyclophosphamide 100 mg/m2/d days 1 to 14, intravenous methotrexate 40 mg/m2 days 1 and 8, intravenous 5‐fluorouracil 600 mg/m2 days 1 and 8, and oral prednisone 40 mg/m2 daily days 1 to 14 (CMFP) for six cycles over 24 weeks
Trial: 1546547
Drug: Clomipramine (25‐75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (25‐75 mg; flexible dosage)
Trial: 27881106
Drug: Multifamily therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifamily therapy (MFT-AN)
Trial: 27881106
Drug: Single family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single family therapy (FT-AN)
Trial: 22709755
Drug: Ranolazine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (1,000 mg twice daily for 7 days)
Trial: 18280116
Drug: 100mg immediate-release
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg immediate-release (IR) tablets
Trial: 18280116
Drug: 250mg controlled-release
RxNorm normalized name: Slo-Niacin 250mg Controlled-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg controlled-release (CR) tablets
Trial: 15699835
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of enteral tube feeding for RV >400 mL in study patients
Trial: 15699835
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of enteral tube feeding for RV >200 mL in controls
Trial: 15699835
Drug: RV <150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV <150 mL
Trial: 15699835
Drug: RV >400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV >400 mL
Trial: 15699835
Drug: RV >300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV >300 mL
Trial: 15699835
Drug: RV >200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV >200 mL
Trial: 15699835
Drug: RV >150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV >150 mL
Trial: 12426766
Drug: Novel drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel drug delivery system with average particle size between 1-150 microns
Trial: 7814484
Drug: Monovalent influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent influenza A/Taiwan/1/86 (H1N1) virus HA, doses ranging from 0 to 405 micrograms per dose
Trial: 7814484
Drug: Trivalent HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent HA vaccine containing A/H1N1, A/H3N2, and influenza B virus HA, doses ranging from 0 to 135 micrograms per strain, 0 to 405 micrograms per dose
Trial: 7814484
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of commercial influenza vaccine (control group)
Trial: 2528230
Drug: Alternative group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative group with 1/5 of the treatment group's exercise program per session
Trial: 17803844
Drug: Paroxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine + Zolpidem (Group A, treated with paroxetine 10 ‐ 20 mg/d and zolpidem 10 mg/d for 4 weeks)
Trial: 12139731
Drug: Increased intensity
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased intensity of therapy
Trial: 8074012
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of cold air (−22 degrees C) during exercise
Trial: 8074012
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of thermoneutral air (22 degrees C) during exercise
Trial: 766497
Drug: Target therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target therapy as per antibiogram
Trial: 766497
Drug: Blind early
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind early therapy with Nifurantin
Trial: 23816952
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of CO2 (all concentrations)
Trial: 17005526
Drug: pH neutral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH neutral, lactate-buffered, low GDP solution (balance)
Trial: 15021447
Drug: Raloxifene (RAL)
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene (RAL) 60 mg/day
Trial: 11710752
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone (0, 25, 50, 100 or 200 mg)
Trial: 2036070
Drug: Madopar HBS
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Madopar HBS (sustained-release preparation)
Trial: 2036070
Drug: Madopar M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Madopar M (standard preparation)
Trial: 27515070
Drug: Ustekinumab (Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (Arm 1: immediate cessation of methotrexate; Arm 2: 4 weeks' overlap with decreasing methotrexate dose)
Trial: 24916903
Drug: Lipocalin-2 treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lipocalin-2 treatment in microglia
Trial: 24916903
Drug: Lipocalin-2 treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lipocalin-2 treatment in astrocytes
Trial: 18409186
Drug: Suspicious Digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspicious Digital Rectal Examination (DRE)
Trial: 10617237
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (LDD) at doses of 0-5 microg/kg/min
Trial: 10617237
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (LDD)
Trial: 1425818
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (bromocriptine + levodopa) for 5 years
Trial: 1425818
Drug: Levodopa alone
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa alone therapy for 5 years
Trial: 1425818
Drug: Maintained combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintained combination therapy for 5 years
Trial: 4065703
Drug: Scheduled intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled intramuscular morphine injections
Trial: 29128486
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose sufentanil (bolus 0.25 µg/kg)
Trial: 29128486
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose sufentanil (bolus 0.5 µg/kg)
Trial: 25496243
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement and immediate temporary restoration
Trial: 25496243
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement and early restoration
Trial: 25496243
Drug: Early implant
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early implant placement and immediate temporary restoration
Trial: 25496243
Drug: Early implant
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early implant placement and early restoration
Trial: 12362542
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily injection of low molecular weight heparin
Trial: 12362542
Drug: Warfarin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin for longer-term secondary prophylaxis
Trial: 12362542
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clinical probability assessment and D-dimer measurement
Trial: 8575688
Drug: High-dose pure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pure follicle-stimulating hormone (pFSH) (Metrodin)
Trial: 2406327
Drug: Low-dose allergoid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose allergoid (maximal dose: 2000 PNU)
Trial: 2406327
Drug: High-dose allergoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose allergoid (maximal dose: 10,000 PNU)
Trial: 30883839
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets 3.5 mg/kg and 5.25 mg/kg
Trial: 26102724
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg/Hydrochlorothiazide 12.5 mg (NH)
Trial: 26102724
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg/Hydrochlorothiazide 12.5 mg (IH)
Trial: 23916740
Drug: Extrafin BDP/F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafin BDP/F 400/24 μg
Trial: 23916740
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose FP/S 1000/100 μg
Trial: 23916740
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose FP/S 500/100 μg
Trial: 16763490
Drug: efavirenz-containing highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz-containing highly active antiretroviral therapy (zidovudine + lamivudine + efavirenz)
Trial: 16763490
Drug: efavirenz-containing highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz-containing highly active antiretroviral therapy
Trial: 9786640
Drug: Mandibular implant-retained
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mandibular implant-retained overdentures (mainly implant-borne on a transmandibular implant)
Trial: 9786640
Drug: Mucosa-borne overdentures
RxNorm normalized name: Sus scrofa oral mucosa preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosa-borne overdentures on two cylindric permucosal IMZ implants